These findings collectively highlight the therapeutic potential of targeting the Nrf2/NOX4 axis to disrupt oxidative stress-driven fibrotic cascades in IPF, and natural products targeting this pathway offer promising therapeutic potential for mitigating oxidative stress and halting fibrosis progression. The gene discussed is NOX4; the disease is idiopathic pulmonary fibrosis.